EGFR and cancer: Small molecule inhibitors that target EGFR are undoubtedly successful, and the first-generation EGFR tyrosine kinase inhibitors (TKIs) (Table 1) such as gefitinib (IRRESA) [10], elotinib (TARCEVA) [11], lapatinib (TYKERB) [12], and icotinib (CONMANA) [13] have efficacy against several types of human cancers.